NextTrip Stock Price, News & Analysis

NextTrip, a travel technology company, has received a notification from Nasdaq indicating non-compliance with Nasdaq Listing Rule 5250(c)(1) due to the delayed filing of its annual report on Form 10-K for the fiscal year ending February 29, 2024. The company now has 60 days to submit a compliance plan to Nasdaq. If accepted, NextTrip may have until December 10, 2024, to meet the filing requirements. Further details are available in the company's Form 8-K filed with the SEC.

Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first batch of synthetic Bryostatin under an exclusive licensing agreement with Stanford University. This development will enable the company to expand its research and conduct trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's disease. The synthetic supply addresses the need for increased availability, crucial for the development of orally deliverable compounds. The company aims to complement ongoing Phase 2 trials in Alzheimer's Disease with additional studies utilizing the new supply.

Synaptogenix, Inc. (OTC: SNPX) has announced the receipt of its first synthetic Bryostatin batch, obtained through an exclusive licensing agreement with Stanford University. This development marks a significant milestone, allowing the company to expand its research initiatives, particularly for an orally deliverable compound. The increased supply will facilitate new clinical trials for various neurodegenerative disorders including Alzheimer's, Multiple Sclerosis, and Parkinson's. Synaptogenix's existing studies include Bryostatin-1, which has a notable safety profile from prior cancer research.

Neurotrope and Metuchen Pharmaceuticals have completed their merger, creating a new public holding company, Petros Pharmaceuticals, trading under the symbol PTPI. Neurotrope shareholders will own approximately 49% and Metuchen shareholders 51% of Petros. This merger includes a spin-off of Neurotrope's existing assets and liabilities. Petros aims to enhance the commercialization of its lead product, Stendra®, an FDA-approved erectile dysfunction treatment, while exploring its potential shift to over-the-counter status. The merger intends to create long-term value for stakeholders.

Neurotrope, Inc. (NASDAQ: NTRP) announced its Board of Directors approved the spin-off of its subsidiary, Neurotrope Bioscience, Inc. (NBI). Shareholders of record on November 30, 2020, will receive one share of NBI for every five shares of Neurotrope held on December 7, 2020. This follows a planned merger with Metuchen Pharmaceuticals, forming a new company named Petros Pharmaceuticals, Inc. The distribution is taxable and subject to specific conditions, including shareholder approval of the merger set for November 25, 2020.

Neurotrope (Nasdaq: NTRP) has initiated a long-term Phase 2 clinical study of Bryostatin-1 for Alzheimer's disease, dosing its first patient. Supported by a $2.7 million NIH grant, this study aims to enroll about 100 patients over six months, evaluating cognitive benefits in the absence of Namenda. Previous pilot trials indicated Bryostatin-1 was well tolerated and showed promising cognitive improvements. The trial represents a key milestone for Neurotrope as it seeks to advance treatment options for Alzheimer's while planning a merger with Metuchen Pharmaceuticals.

Neurotrope has amended its merger agreement with Metuchen Pharmaceuticals, increasing Neurotrope stockholders' ownership in the new company, Petros Pharmaceuticals, to 49%. Originally, it was set at 22.5%. The merger will spin out Neurotrope's lead asset, Bryostatin-1, into a separate entity while Petros focuses on its core products: Stendra® and H-100, a treatment for Peyronie's disease. Petros aims to enhance Stendra's market presence and explore converting it to over-the-counter availability. The transaction is expected to close in the fourth quarter of 2020.

Neurotrope, Inc. (Nasdaq: NTRP) has secured a services agreement with Worldwide Clinical Trials to boost site recruitment for its Phase 2 clinical study of bryostatin-1 aimed at treating moderately severe Alzheimer's disease. Funded by a $2.7 million NIH grant, the study plans to enroll approximately 100 patients over a 6-month period, focusing on cognitive benefits using the Severe Impairment Battery score. The company anticipates dosing the first patient by late Q3 or early Q4 2020, following promising results from prior studies.